With Ad FoxO6 transfection and Ang‐II treatment, FoxO6 overexpression further exacerbated cardiac hypertrophy and increased the expression of β‐MHC, ANP, and TGF‐β1 (Figure S6E–H). The gene discussed is TGFB1; the disease is cardiac hypertrophy.